Phase II Study of 5-Fluorouracil, Oxaliplatin Plus Dasatinib in First-line Metastatic Pancreatic Adenocarcinoma

Trial Profile

Phase II Study of 5-Fluorouracil, Oxaliplatin Plus Dasatinib in First-line Metastatic Pancreatic Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Dasatinib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms FOLFOX-D
  • Most Recent Events

    • 05 Jun 2018 Primary endpoint (Dasatinib activity) has not been met, according to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 Final results (n=42) assessing activity and toxicity of FOLFOX + Dasatinib in previously untreated metastatic pancreatic adenocarcinoma patients, were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 09 Apr 2018 Planned End Date changed from 1 Apr 2018 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top